Carel Industries S.p.A. logo

Carel Industries S.p.A. (CRL)

Market Closed
3 Mar, 15:30
21. 50
-0.85
-3.8%
- Market Cap
- P/E Ratio
- Div Yield
52,722 Volume
- Eps
22.35
Previous Close
Day Range
21.3 22.05
Year Range
13.06 26.3
Want to track CRL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CRL earnings report is expected in 7 days (10 Mar 2026)

Summary

CRL closed today lower at €21.5, a decrease of 3.8% from yesterday's close, completing a monthly increase of 1.42% or €0.3. Over the past 12 months, CRL stock lost -15.52%.
CRL is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2025, missed the consensus estimates by -0.13%. On average, the company has fell short of earnings expectations by -0.14%, based on the last three reports. The next scheduled earnings report is due on Mar 10, 2026.
Carel Industries S.p.A. has completed 1 stock splits, with the recent split occurring on Nov 20, 2023.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NYSE (USD).

CRL Chart

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seekingalpha | 2 hours ago
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term

Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 week ago
Investing in Charles River (CRL)? Don't Miss Assessing Its International Revenue Trends

Investing in Charles River (CRL)? Don't Miss Assessing Its International Revenue Trends

Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks | 1 week ago

Carel Industries S.p.A. (CRL) FAQ

What is the stock price today?

The current price is €21.50.

On which exchange is it traded?

Carel Industries S.p.A. is listed on XMIL.

What is its stock symbol?

The ticker symbol is CRL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.13.

When is the next earnings date?

The next earnings report will release on Mar 10, 2026.

Has Carel Industries S.p.A. ever had a stock split?

Carel Industries S.p.A. had 1 splits and the recent split was on Nov 20, 2023.

Carel Industries S.p.A. Profile

Professional Services Industry
Industrials Sector
James C. Foster CEO
XMIL Exchange
US1598641074 ISIN
US Country
18,700 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.

Products and Services

Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:

  • Genetically Engineered Models and Services: Customization and production of genetically modified animals to meet specific research requirements.
  • Insourcing Solutions: Provision of skilled personnel and resources to manage and operate clients' laboratory animal facilities.
  • Research Animal Diagnostic Services: Comprehensive diagnostic services to ensure the health and genetic integrity of research models.

Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:

  • Early and in vivo Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies, alongside the delivery of preclinical drug and therapeutic candidates ready for safety assessment.
  • Safety Assessment Services: Extensive testing services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics to ensure candidate drugs are safe for clinical trials.

Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses:

  • In vitro Methods for Quality Control: Testing services for both sterile and non-sterile pharmaceuticals and consumer products, including specialized testing of biologics outsourced by pharmaceutical and biotechnology companies.
  • Contract Vivarium Operation Services: Operational support for biopharmaceutical clients’ vivarium facilities, ensuring the maintenance of high-quality standards in animal care and research.

Contact Information

Address: 251 Ballardvale Street
Phone: 781 222 6000